Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 616-623

  Stalc M ^a   Tomsic M ^a   Jezovnik, M K ^a   Poredos P ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Antiphospholipid syndrome; Inflammation; Systemic lupus erythematosus; Thrombosis; Vascular endothelium

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLYCERYL TRINITRATE; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; DIAGNOSTIC AGENT; VASODILATOR AGENT;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC INFLAMMATORY RESPONSE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; BLOOD; CASE CONTROL STUDY; DOPPLER FLOWMETRY; ECHOGRAPHY; HYPEREMIA; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; SLOVENIA; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPEREMIA; INFLAMMATION; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NITROGLYCERIN; SLOVENIA; ULTRASONOGRAPHY, DOPPLER; VASODILATION; VASODILATOR AGENTS;

EID: 80055068205     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. ROMAN MJ, SHANKER BA, DAVIS A et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406
2. ASANUMA Y, OESER A, SHINTANI AK et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15
3. SHOENFELD Y, GERLI R, DORIA A et al.: Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47
4. LEVINE JS, BRANCH DW, RAUCH J: The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63
5. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
6. LEE AB, GODFREY T, ROWLEY KG et al.: Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 2006; 36: 237-43
7. ESDAILE JM, ABRAHAMOWICZ M, GRODZICKY T et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7
8. DEANFIELD JE, HALCOX JP, RABELINK TJ: Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95
9. SITIA S, TOMASONI L, ATZENI F et al.: From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9: 830-4
10. POREDOS P: Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin Appl Thromb Hemost 2001; 7: 276-80
11. LIMA DS, SATO EI, LIMA VC, MIRANDA F JR., HATTA FH: Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292-7
12. JOHNSON SR, HARVEY PJ, FLORAS JS et al.: Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 2004; 13: 590-3
13. EL-MAGADMI M, BODILL H, AHMAD Y et al.: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404
14. CYPIENE A, KOVAITE M, VENALIS A et al.: Arterial wall dysfunction in systemic lupus erythematosus. Lupus 2009; 18: 522-9
15. KAPLAN MJ: Endothelial damage and autoimmune diseases. Autoimmunity 2009; 42: 561-2
16. KAPLANSKI G, CACOUB P, FARNARIER C et al.: Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosusrelated antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 55-64
17. JEZOVNIK MK, POREDOS P, STALC M: Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis. J Atheroscler Thromb 2010; 17: 1190-8
18. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
19. WILSON WA, GHARAVI AE, KOIKE T et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11
20. CUCNIK S, KRIZAJ I, ROZMAN B, KVEDER T, BOZIC B: Concomitant isolation of protein C inhibitor and unnicked beta2-glycoprotein I. Clin Chem Lab Med 2004; 42: 171-4
21. DE LAAT B, DERKSEN RH, VAN LUMMEL M, PENNINGS MT, DE GROOT PG: Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-24
22. CELERMAJER DS, SORENSEN KE, GOOCH VM et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5
23. SZEKANECZ Z, SHOENFELD Y: Lupus and cardiovascular disease: the facts. Lupus 2006; 15: 3-10
24. KAO AH, SABATINE JM, MANZI S: Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003; 15: 519-27
25. COLOMBO BM, CACCIAPAGLIA F, PUNTONI M et al.:Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009; 8: 309-15
26. CUGNO M, BORGHI MO, LONATI LM et al.: Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 2010; 34: 105-10
27. MOSCA M, VIRDIS A, TANI C et al.: Vascular reactivity in patients with undifferentiated connective tissue diseases. Atherosclerosis 2009; 203: 185-91
28. CORRETTI MC, ANDERSON TJ, BENJAMIN EJ et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65
29. AL-QAISI M, KHARBANDA RK, MITTAL TK, DONALD AE: Measurement of endothelial function and its clinical utility for cardiovascular risk. Vasc Health Risk Manag 2008; 4: 647-52
30. HACKMAN A, ABE Y, INSULL W, JR. et al.: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-8
31. CAULIN-GLASER T, FARRELL WJ, PFAU SE et al.: Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998; 31: 1555-60
32. SFIKAKIS PP, CHARALAMBOPOULOS D, VAYIOPOULOS G, OGLESBY R, SFIKAKIS P, TSOKOS GC: Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 5-9
33. JANSSEN BA, LUQMANI RA, GORDON C et al.: Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33: 11126
34. SPRONK PE, BOOTSMA H, HUITEMA MG, LIMBURG PC, KALLENBERG CG: Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994; 97: 439-44
35. SARI RA, TAYSI S, ERDEM F et al.: Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus. Rheumatol Int 2002; 21: 149-52
36. HO CY, WONG CK, LI EK, TAM LS, LAM CW: Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003; 42: 117-22
37. FRIJNS CJ, DERKSEN RH, DE GROOT PG, ALGRA A, FIJNHEER R: Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol 2001; 125: 149-54
38. ZACCAGNI H, FRIED J, CORNELL J, PADILLA P, BREY RL: Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Front Biosci 2004; 9: 1654-9
39. TEN CATE JW, VAN DER POLL T, LEVI M, TEN CATE H, VAN DEVENTER SJ: Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997; 78: 415-9
40. WIMAN B: Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-6
41. BICK RL: Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 2000; 6: 115-25
42. YASUDA S, ATSUMI T, IEKO M, KOIKE T: Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis. Thromb Res 2004; 114: 461-5
43. KEELING DM, CAMPBELL SJ, MACKIE IJ, MACHIN SJ, ISENBERG DA: The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol 1991; 77: 354-9
44. VIOLI F, FERRO D, VALESINI G et al.: Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis. BMJ 1990; 300: 1099-102.